PIA
ENTA icon

Piedmont Investment Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Piedmont Investment Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,992
Closed -$381K – 1031
2019
Q1 		$381K Buy
3,992
+230
+6% +$20.6K 0.02% 677
2018
Q4 		$266K Buy
3,762
+125
+3% +$9.58K 0.01% 793
2018
Q3 		$311K Buy
3,637
+229
+7% +$22.9K 0.01% 767
2018
Q2 		$395K Buy
3,408
+338
+11% +$33.7K 0.02% 528
2018
Q1 		$248K Buy
+3,070
New +$236K 0.01% 639

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Piedmont Investment Advisors's ENTA Position: Q2 2019 in Review

Piedmont Investment Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q2 2019, closing a stake of 3,992 shares — an estimated $381K sold.

Piedmont Investment Advisors first reported a position in ENTA in Q1 2018 and held it in 5 quarters. The position peaked at $395K in Q2 2018. 194 funds tracked by Wall St. Rank hold ENTA as of Q2 2019.

  • Piedmont Investment Advisors reported no remaining Enanta Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Piedmont Investment Advisors sold 3,992 Enanta Pharmaceuticals shares in Q2 2019, an estimated $381K.
  • Piedmont Investment Advisors first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • Piedmont Investment Advisors's Enanta Pharmaceuticals position peaked at $395K in Q2 2018.
  • 194 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2019.

Based on Piedmont Investment Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.